邹 瑛,田道峰,侯亚婷,龙星颖,王慧玲,成 敬.百乐眠胶囊联合艾司西酞普兰片对失眠伴抑郁焦虑患者睡眠质量、不良情绪以及神经递质水平的影响[J].,2021,(8):1465-1468 |
百乐眠胶囊联合艾司西酞普兰片对失眠伴抑郁焦虑患者睡眠质量、不良情绪以及神经递质水平的影响 |
Effect of Bailemen Capsule Combined with Escitalopram Tablet on Sleep Quality, Bad Mood and Neurotransmitter Level of Insomnia Patients with Depression and Anxiety |
投稿时间:2020-07-27 修订日期:2020-08-22 |
DOI:10.13241/j.cnki.pmb.2021.08.014 |
中文关键词: 百乐眠胶囊 失眠伴抑郁焦虑 艾司西酞普兰片 睡眠质量 不良情绪 神经递质 |
英文关键词: Bailemen capsule Insomnia with depression and anxiety Escitalopram tablet Sleep quality Bad mood Neurotransmitter |
基金项目:湖北省卫生计生委指导性项目(WJ2017F1259) |
|
摘要点击次数: 884 |
全文下载次数: 535 |
中文摘要: |
摘要 目的:探讨百乐眠胶囊联合艾司西酞普兰片对失眠伴抑郁焦虑患者睡眠质量、不良情绪以及神经递质水平的影响。方法:选取2017年7月~2019年12月期间我院收治的失眠伴抑郁焦虑患者117例,将上述患者根据随机数字表法分为对照组(n=58,艾司西酞普兰片治疗)和研究组(n=59,百乐眠胶囊联合艾司西酞普兰片治疗),比较两组患者睡眠质量、不良情绪、多导睡眠图(PSG)参数、神经递质水平及不良反应。结果:研究组治疗2个月后的临床总有效率为93.22%(55/59),高于对照组的79.31%(46/58)(P<0.05)。两组治疗2个月后汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)以及匹兹堡睡眠质量指数(PSQI)评分、睡眠潜伏期、P物质(SP)均较治疗前降低,且研究组低于对照组(P<0.05)。两组治疗2个月后睡眠总时间、睡眠效率、神经肽Y(NPY)、5-羟色胺(5-HT)升高,且研究组高于对照组(P<0.05)。治疗期间研究组不良反应发生率较对照组降低(P<0.05)。结论:失眠伴抑郁焦虑患者经百乐眠胶囊联合艾司西酞普兰片治疗后,睡眠质量、不良情绪得到显著改善,同时还可有效改善血清神经递质水平,减少不良反应,临床应用效果确切。 |
英文摘要: |
ABSTRACT Objective: To investigate the effect of Bailemen capsule combined with escitalopram tablet on sleep quality, bad mood and neurotransmitter level in insomnia patients with depression and anxiety. Methods: 117 insomnia patients with depression and anxiety who were admitted to our hospital from July 2017 to December 2019 were selected, they were randomly divided into control group (n=58, treated with escitalopram tablet) and study group (n=59, treated with Bailemian capsule and escitalopram tablet) by random number table method. The sleep quality, bad mood, polysomnography(PSG) parameters, neurotransmitter level and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the study group was 93.22%(55/59), which was higher than 79.31% (46/58) of the control group (P<0.05). The scores of Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD) and Pittsburgh sleep quality index (PSQI), sleep latency and substance P (SP) of the two groups were lower than those before treatment, and the study group was lower than the control group(P<0.05). The total sleep time, sleep efficiency, neuropeptide Y(NPY), 5-hydroxytryptamine (5-HT) in the two groups increased at after 2 months of treatment, and the study group was higher than the control group (P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). Conclusion: After the treatment of insomnia patients with depression and anxiety with baile mian capsule and esitalopram tablet, the quality of sleep and bad mood are improved significantly, and the levels of serum neurotransmitter are also improved effectively, and the adverse reactions are reduced, the effect of clinical application is accurate. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|